Andy Johnson

Andy Johnson is an experienced pharmaceutical professional currently serving as the Head of CMC at Accession Therapeutics Limited since February 2022, where responsibilities include overseeing the development of Active Pharmaceutical Ingredients and Investigational Medicinal Products from pre-clinical stages to clinical readiness. Prior to this role, Andy held multiple positions at Immunocore from September 2008 to February 2022, culminating as Director of Manufacturing and Outsourcing, with a focus on external manufacturing for clinical and commercial programs. Previous experience includes Development Group Leader roles at MediGene AG and Avidex, along with Development Scientist positions at Lonza and British Biotech, showcasing a strong background in pharmaceutical development and scientific leadership.